文献速递免疫规划传染病防控与疫情报告慢病防控与筛查

COVID-19疫苗接种对长新冠综合征的保护作用:一项系统综述与Meta分析

Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis.
PubMed 文献 · Vaccine · 2023-02-08

本研究通过系统综述与Meta分析评估COVID-19疫苗接种与长新冠的关联。感染前两剂接种较未接种(OR 0.64)及一剂接种(OR 0.60)与长新冠风险降低相关。已患长新冠者接种后多数无症状变化(54.4%)。

要点

  • 感染前两剂接种较未接种与长新冠风险降低相关(OR 0.64,95%CI 0.45-0.92)。
  • 两剂接种较一剂接种与长新冠风险降低相关(OR 0.60,95%CI 0.43-0.83)。
  • 持续长新冠者接种后54.4%无症状变化,20.3%报告症状改善。

核心结论

  • 感染SARS-CoV-2前接种COVID-19疫苗与较低的长新冠风险相关,而多数已患长新冠者接种后未经历症状变化。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed和EMBASE(2022年9月,无语言限制,CRD42022360399),纳入前瞻性试验和观察性研究。
  • 纳入6项观察性研究共536,291例未接种和84,603例感染前接种患者(平均年龄41.2-66.6岁;女性9.0-67.3%)。
  • 纳入6项观察性研究共8,199例感染后接种的长新冠患者(平均年龄40.0-53.5岁;女性22.2-85.9%)。
  • 使用随机效应模型合成OR,单组Meta分析合成接种后症状变化。

主要发现

  • 两剂接种较未接种与长新冠风险降低相关(OR 0.64,95%CI 0.45-0.92)。
  • 两剂接种较一剂接种与长新冠风险降低相关(OR 0.60,95%CI 0.43-0.83)。
  • 两剂接种较未接种与持续性疲劳风险降低相关(OR 0.62,95%CI 0.41-0.93)。
  • 两剂接种较未接种与肺部疾病风险降低相关(OR 0.50,95%CI 0.47-0.52)。
  • 持续长新冠症状者中,54.4%(95%CI 34.3-73.1%)接种后未报告症状变化;20.3%(95%CI 8.1-42.4%)在接种后2周至6个月经历症状改善。

关键数值与推荐

  • 两剂接种较未接种的长新冠OR为0.64(95%CI 0.45-0.92)。
  • 两剂接种较一剂接种的长新冠OR为0.60(95%CI 0.43-0.83)。
  • 两剂接种较未接种的持续性疲劳OR为0.62(95%CI 0.41-0.93)。
  • 两剂接种较未接种的肺部疾病OR为0.50(95%CI 0.47-0.52)。
  • 持续长新冠者接种后无症状变化比例为54.4%(95%CI 34.3-73.1%),症状改善比例为20.3%(95%CI 8.1-42.4%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The relationship between coronavirus disease 2019 (COVID-19) vaccination and long COVID has not been firmly established. We conducted a systematic review and meta-analysis to evaluate the association between COVID-19 vaccination and long COVID. METHODS: PubMed and EMBASE databases were searched on September 2022 without language restrictions (CRD42022360399) to identify prospective trials and observational studies comparing patients with and without vaccination before severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. We also included studies reporting symptomatic changes of ongoing long COVID following vaccination among those with a history of SARS-CoV-2 infection. Odds ratios (ORs) for each outcome were synthesized using a random-effects model. Symptomatic changes after vaccination were synthesized by a one-group meta-analysis. RESULTS: Six observational studies involving 536,291 unvaccinated and 84,603 vaccinated (before SARS-CoV-2 infection) patients (mean age, 41.2-66.6; female, 9.0-67.3%) and six observational studies involving 8,199 long COVID patients (mean age, 40.0 to 53.5; female, 22.2-85.9%) who received vaccination after SARS-CoV-2 infection were included. Two-dose vaccination was associated with a lower risk of long COVID compared to no vaccination (OR, 0.64; 95% confidence interval [CI], 0.45-0.92) and one-dose vaccination (OR, 0.60; 95% CI, 0.43-0.83). Two-dose vaccination compared to no vaccination was associated with a lower risk of persistent fatigue (OR, 0.62; 95% CI, 0.41-0.93) and pulmonary disorder (OR, 0.50; 95% CI, 0.47-0.52). Among those with ongoing long COVID symptoms, 54.4% (95% CI, 34.3-73.1%) did not report symptomatic changes following vaccination, while 20.3% (95% CI, 8.1-42.4%) experienced symptomatic improvement after two weeks to six months of COVID-19 vaccination. CONCLUSIONS: COVID-19 vaccination before SARS-CoV-2 infection was associated with a lower risk of long COVID, while most of those with ongoing long COVID did not experience symptomatic changes following vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Watanabe A, Iwagami M, Yasuhara J, et al. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. 2023. PMID: 36774332. doi:10.1016/j.vaccine.2023.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。